A roadmap for developing and engineering in vitro pulmonary fibrosis models.

Area of Science:

• Biomedical Engineering
• Pulmonary Medicine
• Cell Biology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no cure, challenging diagnosis, and limited treatment options.
• Current treatments like nintedanib and pirfenidone only slow IPF progression, and animal models often fail to predict human drug efficacy.
• Recent research highlights the extracellular matrix (ECM) role in IPF, shifting focus from cellular to microenvironmental factors in disease development.

Purpose of the Study:

• To review the critical role of the extracellular matrix (ECM) in idiopathic pulmonary fibrosis (IPF) pathogenesis.
• To outline the development of advanced in vitro models that better mimic the human lung microenvironment for IPF research.
• To provide a roadmap for creating improved in vitro models for understanding IPF mechanisms and developing novel therapeutics.

Main Methods:

• Review of current literature on pulmonary fibrosis, ECM biology, and in vitro modeling techniques.
• Focus on fibroblasts and myofibroblasts as key cell types in ECM-driven fibrotic processes.
• Discussion of relevant 3D microenvironment parameters crucial for recapitulating IPF pathology in vitro.

Main Results:

• The extracellular matrix (ECM) plays a significant role in IPF, interacting with cells to promote fibrosis.
• Existing in vitro models have limitations in replicating the complex biochemical and biomechanical cues of the human lung microenvironment.
• Advanced in vitro models are necessary to bridge the gap between preclinical studies and clinical efficacy for IPF drug candidates.

Conclusions:

• A shift towards understanding ECM's role in IPF necessitates the development of more sophisticated in vitro models.
• Advanced 3D in vitro systems are crucial for accurately studying IPF mechanisms and identifying effective drug targets.
• Future research should focus on creating in vitro models that recapitulate the lung microenvironment to accelerate the development of IPF treatments.